Genome editing in the treatment of ocular diseases

참고문헌 (205)

1. Porteus, M. H., "A new class of medicines through DNA editing", N. Engl. J. Med, 380, pp.947~959 (2019)
2. Anzalone, A. V., "Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors", Nat. Biotechnol, 38, pp.824~844 (2020)
3. Jinek, M., "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", Science, 337, pp.816~821 (2012)
4. Doudna, J. A., "Genome editing. The new frontier of genome engineering with CRISPR-Cas9", Science, 346, pp.1258096~ (2014)
5. Wang, J. Y., "CRISPR technology: a decade of genome editing is only the beginning", Science, 379, pp.eadd8643~ (2023)
6. Komor, A. C., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", Nature, 533, pp.420~424 (2016)
7. Gaudelli, N. M., "Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage", Nature, 551, pp.464~471 (2017)
8. Anzalone, A. V., "Search-and-replace genome editing without double-strand breaks or donor DNA", Nature, 576, pp.149~157 (2019)
9. Newby, G. A., "In vivo somatic cell base editing and prime editing", Mol. Ther, 29, pp.3107~3124 (2021)
10. Rees, H. A., "Base editing : precision chemistry on the genome and transcriptome of living cells", Nat. Rev. Genet, 19, pp.770~788 (2018)
11. Chen, P. J., "Prime editing for precise and highly versatile genome manipulation", Nat. Rev. Genet, 24, pp.161~177 (2023)
12. Caruso, S. M., "CRISPR", Cas therapeutic strategies for autosomal dominant disorders, 2022, pp.132, e158287~
13. Suh, S., "Precision genome editing in the eye", Proc. Natl Acad. Sci. USA, 119, pp.e2210104119~ (2022)
14. Yan, A. L., "Genome editing, a superior therapy for inherited retinal diseases", Vis. Res, 206, pp.108192~ (2023)
15. Du, S. W., "Eye on genome editing", J. Exp. Med, 220, pp.e20230146~ (2023)
16. Palczewska, G., "Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyes", Nat. Med, 16, pp.1444~1449 (2010)
17. Palczewska, G., "Noninvasive two-photon microscopy imaging of mouse retina and retinal pigment epithelium through the pupil of the eye", Nat. Med, 20, pp.785~789 (2014)
18. Palczewska, G., "Noninvasive two-photon optical biopsy of retinal fluorophores", Proc. Natl Acad. Sci. USA, 117, pp.22532~22543 (2020)
19. Boguslawski, J., "In vivo imaging of the human eye using a 2-photon-excited fluorescence scanning laser ophthalmoscope", J. Clin. Invest, 132, pp.e154218~ (2022)
20. Palczewska, G., "From mouse to human : accessing the biochemistry of vision in vivo by two-photon excitation", Prog. Retin. Eye Res, 93, pp.101170~ (2023)
21. Ishino, Y., "Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product", J. Bacteriol, 169, pp.5429~5433 (1987)
22. Mojica, F. J., "Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria", Mol. Microbiol, 36, pp.244~246 (2000)
23. Jansen, R., "Identification of genes that are associated with DNA repeats in prokaryotes", Mol. Microbiol, 43, pp.1565~1575 (2002)
24. Mojica, F. J., "Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements", J. Mol. Evol, 60, pp.174~182 (2005)
25. Bolotin, A., "Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin", Microbiology, 151, pp.2551~2561 (2005)
26. Pourcel, C., "CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies", Microbiology, 151, pp.653~663 (2005)
27. Barrangou, R., "CRISPR provides acquired resistance against viruses in prokaryotes", Science, 315, pp.1709~1712 (2007)
28. Makarova, K. S., "A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action", Biol. Direct, 1, pp.7~ (2006)
29. Makarova, K. S., "Evolution and classification of the CRISPR–Cas systems", Nat. Rev. Microbiol, 9, pp.467~477 (2011)
30. van der Oost, J., "Unravelling the structural and mechanistic basis of CRISPR–Cas systems", Nat. Rev. Microbiol, 12, pp.479~492 (2014)
31. Gasiunas, G., "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", Proc. Natl Acad. Sci. USA, 109, pp.E2579~E2586 (2012)
32. Ceccaldi, R., "Repair pathway choices and consequences at the double-strand break", Trends Cell Biol, 26, pp.52~64 (2016)
33. Carroll, D., "Genome engineering with targetable nucleases", Annu. Rev. Biochem, 83, pp.409~439 (2014)
34. Doudna, J. A., "The new frontier of genome engineering with CRISPR-Cas9", Science, 346, pp.1258096~ (2014)
35. Maruyama, T., "Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining", Nat. Biotechnol, 33, pp.538~542 (2015)
36. Cong, L., "Multiplex genome engineering using CRISPR", Cas systems, 2013, pp.339, 819~823
37. Musunuru, K., "In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates", Nature, 593, pp.429~434 (2021)
38. Koblan, L. W., "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction", Nat. Biotechnol, 36, pp.843~846 (2018)
39. Anzalone, A. V., "Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors", Nat. Biotechnol, 38, pp.824~844 (2020)
40. Lin, Q., "Prime genome editing in rice and wheat", Nat. Biotechnol, 38, pp.582~585 (2020)
41. Nishimasu, H., "Crystal structure of Cas9 in complex with guide RNA and target DNA", Cell, 156, pp.935~949 (2014)
42. Jiang, F., "CRISPR–Cas9 structures and mechanisms", Annu. Rev. Biophys, 46, pp.505~529 (2017)
43. Nishida, K., "Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems", Science, 353, pp.aaf8729~ (2016)
44. Li, X., "Base editing with a Cpf1-cytidine deaminase fusion", Nat. Biotechnol, 36, pp.324~327 (2018)
45. Song, Y., "Large-fragment deletions induced by Cas9 cleavage while not in the BEs system", Mol. Ther. Nucleic Acids, 21, pp.523~526 (2020)
46. Komor, A. C., "CRISPR-based technologies for the manipulation of eukaryotic genomes", Cell, 168, pp.20~36 (2017)
47. Ryu, S. -M., "Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy", Nat. Biotechnol, 36, pp.536~539 (2018)
48. Suh, S., "Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing", Nat. Biomed. Eng, 5, pp.169~178 (2021)
49. Koblan, L. W., "In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice", Nature, 589, pp.608~614 (2021)
50. Newby, G. A., "Base editing of haematopoietic stem cells rescues sickle cell disease in mice", Nature, 595, pp.295~302 (2021)
51. Choi, E. H., "In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration", Nat. Commun, 13, pp.1830~ (2022)
52. Reichart, D., "Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice", Nat. Med, 29, pp.412~421 (2023)
53. Komor, A. C., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity", Sci. Adv, 3, pp.eaao4774~ (2017)
54. Zafra, M. P., "Optimized base editors enable efficient editing in cells, organoids and mice", Nat. Biotechnol, 36, pp.888~893 (2018)
55. Richter, M. F., "Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity", Nat. Biotechnol, 38, pp.883~891 (2020)
56. Miller, S. M., "Phage-assisted continuous and non-continuous evolution", Nat. Protoc, 15, pp.4101~4127 (2020)
57. Gaudelli, N. M., "Directed evolution of adenine base editors with increased activity and therapeutic application", Nat. Biotechnol, 38, pp.892~900 (2020)
58. Jin, S., "Cytosine, but not adenine, base editors induce genome-wide offtarget mutations in rice", Science, 364, pp.292~ (2019)
59. Zuo, E., "Cytosine base editor generates substantial off-target singlenucleotide variants in mouse embryos", Science, 364, pp.289~292 (2019)
60. Gao, R., "Genomic and transcriptomic analyses of prime editing guide RNA–independent off-target effects by prime editors", CRISPR J, 5, pp.276~293 (2022)
61. Park, S. -J., "Targeted mutagenesis in mouse cells and embryos using an enhanced prime editor", Genome Biol, 22, pp.170~ (2021)
62. Velimirovic, M., "Peptide fusion improves prime editing efficiency", Nat. Commun, 13, pp.3512~ (2022)
63. Song, M., "Generation of a more efficient prime editor 2 by addition of the Rad51 DNA-binding domain", Nat. Commun, 12, pp.5617~ (2021)
64. Nelson, J. W., "Engineered pegRNAs improve prime editing efficiency", Nat. Biotechnol, 40, pp.402~410 (2022)
65. Zhang, G., "Enhancement of prime editing via xrRNA motif-joined pegRNA", Nat. Commun, 13, pp.1856~ (2022)
66. Anzalone, A. V., "Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing", Nat. Biotechnol, 40, pp.731~740 (2022)
67. Liu, N., "HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing", Mol. Ther. Nucleic Acids, 29, pp.36~46 (2022)
68. Chen, P. J., "Enhanced prime editing systems by manipulating cellular determinants of editing outcomes", Cell, 184, pp.5635~5652 (2021)
69. Kevany, B. M., "Phagocytosis of retinal rod and cone photoreceptors", Physiology, 25, pp.8~15 (2010)
70. Kiser, P. D., "Retinoids and retinal diseases", Annu. Rev. Vis. Sci, 2, pp.197~234 (2016)
71. Flaxman, S. R., "Global causes of blindness and distance vision impairment 1990-2020 : a systematic review and meta-analysis", Lancet Glob. Health, 5, pp.e1221~e1234 (2017)
72. Taylor, A., "Ocular immune privilege", Eye, 23, pp.1885~1889 (2009)
73. Streilein, J. W., "Ocular immune privilege : therapeutic opportunities from an experiment of nature", Nat. Rev. Immunol, 3, pp.879~889 (2003)
74. Sapino, S., "Ocular drug delivery : a special focus on the thermosensitive approach", Nanomaterials, 9, pp.884~ (2019)
75. Dias, M. F., "Molecular genetics and emerging therapies for retinitis pigmentosa : basic research and clinical perspectives", Prog. Retin. Eye Res, 63, pp.107~131 (2018)
76. Kumar, S., "RNA-targeting strategies as a platform for ocular gene therapy", Prog. Retin. Eye Res, 92, pp.101110~ (2023)
77. Jo, D. H., "In vivo application of base and prime editing to treat inherited retinal diseases", Prog. Retin. Eye Res, 94, pp.101132~ (2023)
78. Russell, S., "Efficacy and safety of voretigene neparvovec(AAV2-hRPE65v2)in patients with RPE65-mediated inherited retinal dystrophy : a randomised, controlled, open-label, phase 3 trial", Lancet, 390, pp.849~860 (2017)
79. Bainbridge, J. W., "Long-term effect of gene therapy on Leber’s congenital amaurosis", N. Engl. J. Med, 372, pp.1887~1897 (2015)
80. Jacobson, S. G., "Improvement and decline in vision with gene therapy in childhood blindness", N. Engl. J. Med, 372, pp.1920~1926 (2015)
81. Cideciyan, A. V., "Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement", Proc. Natl Acad. Sci. USA, 110, pp.E517~E525 (2013)
82. Gardiner, K. L., "Long-term structural outcomes of late-stage RPE65 gene therapy", Mol. Ther, 28, pp.266~278 (2020)
83. Eghrari, A. O., "Overview of the cornea : structure, function, and development", Prog. Mol. Biol. Transl. Sci, 134, pp.7~23 (2015)
84. Meek, K. M., "Changes in the refractive index of the stroma and its extrafibrillar matrix when the cornea swells", Biophys. J, 85, pp.2205~2212 (2003)
85. Liesegang, T. J., "Herpes simplex virus epidemiology and ocular importance", Cornea, 20, pp.1~13 (2001)
86. Iliff, B. W., "The genetics of Fuchs’ corneal dystrophy", Expert Rev. Ophthalmol, 7, pp.363~375 (2012)
87. Munier, F. L., "Kerato-epithelin mutations in four 5q31-linked corneal dystrophies", Nat. Genet, 15, pp.247~251 (1997)
88. Farooq, A. V., "Herpes simplex epithelial and stromal keratitis : an epidemiologic update", Surv. Ophthalmol, 57, pp.448~462 (2012)
89. Weerasooriya, S., "Herpes simplex virus 1 ICP8 mutant lacking annealing activity is deficient for viral DNA replication", Proc. Natl Acad. Sci. USA, 116, pp.1033~1042 (2019)
90. Weller, S. K., "Herpes simplex viruses : mechanisms of DNA replication", Cold Spring Harb. Perspect. Biol, 4, pp.a013011~ (2012)
91. Yin, D., "Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice", Nat. Biotechnol, 39, pp.567~577 (2021)
92. Wei, A., "In vivo CRISPR gene editing in patients with herpes stromal keratitis", medRxiv, ~ (2023)
93. Gottsch, J. D., "Inheritance of a novel COL8A2 mutation defines a distinct early-onset subtype of Fuchs corneal dystrophy", Invest. Ophthalmol. Vis. Sci, 46, pp.1934~1939 (2005)
94. Biswas, S., "Missense mutations in COL8A2, the gene encoding the alpha2chain of type VIII collagen, cause two forms of corneal endothelial dystrophy", Hum. Mol. Genet, 10, pp.2415~2423 (2001)
95. Jun, A. S., "An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis", Hum. Mol. Genet, 21, pp.384~393 (2012)
96. Meng, H., "L450W and Q455K Col8a2 knock-in mouse models of Fuchs endothelial corneal dystrophy show distinct phenotypes and evidence for altered autophagy", Invest. Ophthalmol. Vis. Sci, 54, pp.1887~1897 (2013)
97. Uehara, H., "Start codon disruption with CRISPR", Cas9 prevents murine Fuchs’ endothelial corneal dystrophy, 2021, pp.10, e55637~
98. Lakshminarayanan, R., "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies", Ocul. Surf, 12, pp.234~251 (2014)
99. Akiya, S., "Granular-lattice(Avellino)corneal dystrophy", Ophthalmologica, 213, pp.58~62 (1999)
100. Folberg, R., "Clinically atypical granular corneal dystrophy with pathologic features of lattice-like amyloid deposits. A study of these families", Ophthalmology, 95, pp.46~51 (1988)
101. Moon, J. W., "Homozygous granular corneal dystrophy type II(Avellino corneal dystrophy) : natural history and progression after treatment", Cornea, 26, pp.1095~1100 (2007)
102. Watanabe, H., "Two patterns of opacity in corneal dystrophy caused by the homozygous BIG-H3 R124H mutation", Am. J. Ophthalmol, 132, pp.211~216 (2001)
103. Dinh, R., "Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy", Ophthalmology, 106, pp.1490~1497 (1999)
104. Lyons, C. J., "Granular corneal dystrophy. Visual results and pattern of recurrence after lamellar or penetrating keratoplasty", Ophthalmology, 101, pp.1812~1817 (1994)
105. Taketani, Y., "Repair of the TGFBI gene in human corneal keratocytes derived from a granular corneal dystrophy patient via CRISPR", Cas9-induced homologydirected repair, 2017, pp.7, 16713~
106. Weinreb, R. N., "The pathophysiology and treatment of glaucoma: a review", JAMA, 311, pp.1901~1911 (2014)
107. Tham, Y. C., "Global prevalence of glaucoma and projections of glaucoma burden through 2040 : a systematic review and meta-analysis", Ophthalmology, 121, pp.2081~2090 (2014)
108. Weinreb, R. N., "Primary open-angle glaucoma", Lancet, 363, pp.1711~1720 (2004)
109. Stone, E. M., "Identification of a gene that causes primary open angle glaucoma", Science, 275, pp.668~670 (1997)
110. Goldenstein, H., "Haptoglobin genotype and its role in determining heme-iron mediated vascular disease", Pharmacol. Res, 66, pp.1~6 (2012)
111. Kasetti, R. B., "Autophagy stimulation reduces ocular hypertension in a murine glaucoma model via autophagic degradation of mutant myocilin", JCI Insight, 6, pp.e143359~ (2021)
112. Jain, A., "CRISPR-Cas9-based treatment of myocilin-associated glaucoma", Proc. Natl Acad. Sci. USA, 114, pp.11199~11204 (2017)
113. Wu, J., "Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9", Mol. Ther, 28, pp.820~829 (2020)
114. Derynck, R., "Specificity, versatility, and control of TGF-β family signaling", Sci. Signal, 12, pp.eaav5183~ (2019)
115. Cousins, S. W., "Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor", Invest. Ophthalmol. Vis. Sci, 32, pp.2201~2211 (1991)
116. Granstein, R. D., "Aqueous humor contains transforming growth factor-beta and a small(less than 3500 daltons)inhibitor of thymocyte proliferation", J. Immunol, 144, pp.3021~3027 (1990)
117. Jampel, H. D., "Transforming growth factorbeta in human aqueous humor", Curr. Eye Res, 9, pp.963~969 (1990)
118. Ozcan, A. A., "The aqueous levels of TGF-beta2 in patients with glaucoma", Int. Ophthalmol, 25, pp.19~22 (2004)
119. Yamamoto, N., "Concentration of transforming growth factor beta2 in aqueous humor", Ophthalmic Res, 37, pp.29~33 (2005)
120. Trivedi, R. H., "Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes", J. Ocul. Pharm. Ther, 27, pp.477~480 (2011)
121. Pena, J. D., "Transforming growth factor beta isoforms in human optic nerve heads", Br. J. Ophthalmol, 83, pp.209~218 (1999)
122. Rayana, N. P., "Using CRISPR interference as a therapeutic approach to treat TGFβ2-induced ocular hypertension and glaucoma", Invest. Ophthalmol. Vis. Sci, 62, pp.7~ (2021)
123. Gilbert, L. A., "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes", Cell, 154, pp.442~451 (2013)
124. Thakore, P. I., "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements", Nat. Methods, 12, pp.1143~1149 (2015)
125. Carmeliet, P., "Angiogenesis in health and disease", Nat. Med, 9, pp.653~660 (2003)
126. Wong, T. Y., "Diabetic retinopathy", Nat. Rev. Dis. Prim, 2, pp.16012~ (2016)
127. Hellström, A., "Retinopathy of prematurity", Lancet, 382, pp.1445~1457 (2013)
128. Jager, R. D., "Age-related macular degeneration", N. Engl. J. Med, 358, pp.2606~2617 (2008)
129. Guymer, R. H., "Age-related macular degeneration", Lancet, 401, pp.P1459~P1472 (2023)
130. Campochiaro, P. A., "Molecular pathogenesis of retinal and choroidal vascular diseases", Prog. Retin. Eye Res, 49, pp.67~81 (2015)
131. Miller, J. W., "Vascular endothelial growth factor A in intraocular vascular disease", Ophthalmology, 120, pp.106~114 (2013)
132. Holmgaard, A., "In vivo knockout of the Vegfa gene by lentiviral delivery of CRISPR", Cas9 in mouse retinal pigment epithelium cells, 2017, pp.9, 89~99
133. Koo, T., "CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration", Nat. Commun, 9, pp.1855~ (2018)
134. Ling, S., "Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfatargeting guide RNA prevents wet age-related macular degeneration in mice", Nat. Biomed. Eng, 5, pp.144~156 (2021)
135. Kim, K., "Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration", Genome Res, 27, pp.419~426 (2017)
136. Chung, S. H., "CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization", Mol. Ther. Nucleic Acids, 28, pp.613~622 (2022)
137. Mitchell, G. A., "An initiator codon mutation in ornithine-deltaaminotransferase causing gyrate atrophy of the choroid and retina", J. Clin. Investig, 81, pp.630~633 (1988)
138. Duncan, J. L., "Inherited retinal degenerations : current landscape and knowledge gaps", Transl. Vis. Sci. Technol, 7, pp.6~ (2018)
139. Thompson, D. A., "Advancing clinical trials for inherited retinal diseases : recommendations from the Second Monaciano Symposium", Transl. Vis. Sci. Technol, 9, pp.2~ (2020)
140. Georgiou, M., "Inherited retinal diseases : therapeutics, clinical trials and end points—a review", Clin. Exp. Ophthalmol, 49, pp.270~288 (2021)
141. Cideciyan, A. V., "Measures of function and structure to determine phenotypic features, natural history, and treatment outcomes in inherited retinal diseases", Annu. Rev. Vis. Sci, 7, pp.747~772 (2021)
142. Verbakel, S. K., "Non-syndromic retinitis pigmentosa", Prog. Retin. Eye Res, 66, pp.157~186 (2018)
143. Hosseini Shabanan, S., "Stem cell transplantation as a progressing treatment for retinitis pigmentosa", Cell Tissue Res, 387, pp.177~205 (2022)
144. Stingl, K., "Subretinal visual implant Alpha IMS—clinical trial interim report", Vis. Res, 111, pp.149~160 (2015)
145. Merkle, F. T., "Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations", Nature, 545, pp.229~233 (2017)
146. Petrs-Silva, H., "Advances in gene therapy technologies to treat retinitis pigmentosa", Clin. Ophthalmol, 8, pp.127~136 (2014)
147. Bakondi, B., "In vivo CRISPR", Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa, 2016, pp.24, 556~563
148. Giannelli, S. G., "Cas9", sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery, 2018, pp.27, 761~779
149. Gumerson, J. D., "Restoration of RPGR expression in vivo using CRISPR", Cas9gene editing, 2022, pp.29, 81~93
150. Cai, Y., "In vivo genome editing rescues photoreceptor degeneration via a Cas9", RecA-mediated homology-directed repair pathway, 2019, pp.5, eaav3335~
151. Qin, H., "Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas", J. Exp. Med, 220, pp.e20220776~ (2023)
152. Tanna, P., "Stargardt disease : clinical features, molecular genetics, animal models and therapeutic options", Br. J. Ophthalmol, 101, pp.25~30 (2017)
153. Fujinami, K., "Clinical and molecular characteristics of childhood-onset Stargardt disease", Ophthalmology, 122, pp.326~334 (2015)
154. Molday, L. L., "ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy", Nat. Genet, 25, pp.257~258 (2000)
155. Allikmets, R., "A photoreceptor cell-specific ATP-binding transporter gene(ABCR)is mutated in recessive Stargardt macular dystrophy", Nat. Genet, 15, pp.236~246 (1997)
156. Molday, R. S., "Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration", Prog. Retin. Eye Res, 89, pp.101036~ (2022)
157. Cideciyan, A. V., "Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle : a reappraisal of the human disease sequence", Hum. Mol. Genet, 13, pp.525~534 (2004)
158. Beharry, S., "N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4(ABCR)", J. Biol. Chem, 279, pp.53972~53979 (2004)
159. Quazi, F., "ABCA4 is an N-retinylidenephosphatidylethanolamine and phosphatidylethanolamine importer", Nat. Commun, 3, pp.925~ (2012)
160. Chen, Y., "Mechanism of all-trans-retinal toxicity with implications for Stargardt disease and age-related macular degeneration", J. Biol. Chem, 287, pp.5059~5069 (2012)
161. Weng, J., "Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice", Cell, 98, pp.13~23 (1999)
162. Grieger, J. C., "Packaging capacity of adeno-associated virus serotypes : impact of larger genomes on infectivity and postentry steps", J. Virol, 79, pp.9933~9944 (2005)
163. Zernant, J., "Analysis of the ABCA4 genomic locus in Stargardt disease", Hum. Mol. Genet, 23, pp.6797~6806 (2014)
164. Sangermano, R., "ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in Stargardt disease", Genome Res, 28, pp.100~110 (2018)
165. Scotti, M. M., "RNA mis-splicing in disease", Nat. Rev. Genet, 17, pp.19~32 (2016)
166. Cartegni, L., "Listening to silence and understanding nonsense : exonic mutations that affect splicing", Nat. Rev. Genet, 3, pp.285~298 (2002)
167. Ong, C. T., "Enhancer function : new insights into the regulation of tissue-specific gene expression", Nat. Rev. Genet, 12, pp.283~293 (2011)
168. De Angeli, P., "Effective splicing restoration of a deep-intronic ABCA4 variant in cone photoreceptor precursor cells by CRISPR", SpCas9 approaches, 2022, pp.29, 511~524
169. den Hollander, A. I., "Leber congenital amaurosis : genes, proteins and disease mechanisms", Prog. Retin. Eye Res, 27, pp.391~419 (2008)
170. Kumaran, N., "Leber congenital amaurosis", early-onset severe retinal dystrophy : clinical features, molecular genetics and therapeutic interventions, 2017, pp.101, 1147~1154
171. Bennett, J., "Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations : a follow-on phase 1 trial", Lancet, 388, pp.661~672 (2016)
172. Maguire, A. M., "Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy : results of phase 1 and 3 trials", Ophthalmology, 126, pp.1273~1285 (2019)
173. Rachel, R. A., "Photoreceptor sensory cilia and ciliopathies : focus on CEP290, RPGR and their interacting proteins", Cilia, 1, pp.22~ (2012)
174. Perrault, I., "Spectrum of NPHP6", CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype, 2007, pp.28, 416~
175. Vallespin, E., "Frequency of CEP290 c.2991_1655A>G mutation in 175Spanish families affected with Leber congenital amaurosis and early-onset retinitis pigmentosa", Mol. Vis, 13, pp.2160~2162 (2007)
176. den Hollander, A. I., "Mutations in the CEP290(NPHP6)gene are a frequent cause of Leber congenital amaurosis", Am. J. Hum. Genet, 79, pp.556~561 (2006)
177. Maeder, M. L., "Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10", Nat. Med, 25, pp.229~233 (2019)
178. Cai, X., "RPE65 : role in the visual cycle, human retinal disease, and gene therapy", Ophthalmic Genet, 30, pp.57~62 (2009)
179. Jo, D. H., "CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis", Sci. Adv, 5, pp.eaax1210~ (2019)
180. Jang, H. -K., "High-purity production and precise editing of DNA base editing ribonucleoproteins", Sci. Adv, 7, pp.eabg2661~ (2021)
181. Jang, H., "Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases", Nat. Biomed. Eng, 6, pp.181~194 (2022)
182. Reichel, F. F., "AAV8 can induce innate and adaptive immune response in the primate eye", Mol. Ther, 25, pp.2648~2660 (2017)
183. Xiong, W., "AAV cis-regulatory sequences are correlated with ocular toxicity", Proc. Natl Acad. Sci. USA, 116, pp.5785~5794 (2019)
184. Bainbridge, J. W., "Effect of gene therapy on visual function in Leber’s congenital amaurosis", N. Engl. J. Med, 358, pp.2231~2239 (2008)
185. Dimopoulos, I. S., "Two-year results after AAV2-mediated gene therapy for choroideremia : the Alberta experience", Am. J. Ophthalmol, 193, pp.130~142 (2018)
186. Dalkara, D., "In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous", Sci. Transl. Med, 5, pp.189ra176~ (2013)
187. Chan, Y. K., "Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses", Sci. Transl. Med, 13, pp.eabd3438~ (2021)
188. Toral, M. A., "Investigation of Cas9 antibodies in the human eye", Nat. Commun, 13, pp.1053~ (2022)
189. Chandler, R. J., "Recombinant adeno-associated viral integration and genotoxicity : insights from animal models", Hum. Gene Ther, 28, pp.314~322 (2017)
190. Donsante, A., "Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors", Gene Ther, 8, pp.1343~1346 (2001)
191. Finn, J. D., "A single administration of CRISPR", Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing, 2018, pp.22, 2227~2235
192. Lyu, P., "Delivering Cas9", sgRNA ribonucleoprotein(RNP)by lentiviral capsid-based bionanoparticles for efficient ‘hit-andrun’genome editing, 2019, pp.47, e99~
193. Mangeot, P. E., "Genome editing in primary cells and in vivo using viralderived nanoblades loaded with Cas9-sgRNA ribonucleoproteins", Nat. Commun, 10, pp.45~ (2019)
194. Banskota, S., "Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins", Cell, 185, pp.250~265 (2022)
195. Patel, S. R., "Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye", Invest. Ophthalmol. Vis. Sci, 53, pp.4433~4441 (2012)
196. Olsen, T. W., "Drug tissue distribution of TUDCA from a biodegradable suprachoroidal implant versus intravitreal or systemic delivery in the pig model", Transl. Vis. Sci. Technol, 9, pp.11~ (2020)
197. Muya, L., "Suprachoroidal injection of triamcinolone acetonide suspension : ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina", J. Ocul. Pharm. Ther, 38, pp.459~467 (2022)
198. Yeh, S., "Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis : phase 3 randomized trial", Ophthalmology, 127, pp.948~955 (2020)
199. Barakat, M. R., "Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema : a randomized, double-masked, parallel-design, controlled study", Ophthalmol. Retin, 5, pp.60~70 (2021)
200. Campochiaro, P. A., "Suprachoroidal triamcinolone acetonide for retinal vein occlusion : results of the tanzanite study", Ophthalmol. Retin, 2, pp.320~328 (2018)
201. Jung, J. H., "Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space", J. Control Release, 352, pp.472~484 (2022)
202. Shen, J., "Suprachoroidal gene transfer with nonviral nanoparticles", Sci. Adv, 6, pp.eaba1606~ (2020)
203. Ding, K., "AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression", J. Clin. Invest, 129, pp.4901~4911 (2019)
204. Kansara, V. S., "Suprachoroidally delivered DNA nanoparticles transfect retina and retinal pigment epithelium", choroid in rabbits, 2020, pp.9, 21~
205. Xu, D., "Creating an ocular biofactory: surgical approaches in gene therapy for acquired retinal diseases", Asia Pac. J. Ophthalmol, 10, pp.5~11 (2021)

관련 논문AI추천